Compare CORT & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CORT | HALO |
|---|---|---|
| Founded | 1998 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 9.9B |
| IPO Year | 2001 | 2001 |
| Metric | CORT | HALO |
|---|---|---|
| Price | $111.91 | $103.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $96.50 | $78.64 |
| AVG Volume (30 Days) | 1.3M | ★ 2.0M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.09 | ★ 3.11 |
| Revenue | ★ $761,407,000.00 | $151,862,000.00 |
| Revenue This Year | $26.08 | $28.24 |
| Revenue Next Year | $26.98 | $12.56 |
| P/E Ratio | $1,267.14 | ★ $33.09 |
| Revenue Growth | ★ 12.79 | N/A |
| 52 Week Low | $28.66 | $61.23 |
| 52 Week High | $122.21 | $104.77 |
| Indicator | CORT | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 65.59 | 87.77 |
| Support Level | $76.41 | $62.89 |
| Resistance Level | $122.21 | N/A |
| Average True Range (ATR) | 5.21 | 3.17 |
| MACD | 0.55 | 2.18 |
| Stochastic Oscillator | 72.40 | 95.28 |
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.